InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.535 0.325 (26.86%)+
Announcement
Release
15 Apr 2026 10:53AM
Price at Release
$1.210
Full Release
download
Summary
PYC Therapeutics Limited, a precision medicine company based in Perth, Australia, announced the progression to a multi-dose study in their ADOA program. The Safety Review Committee approved the transition after a successful review of safety and tolerability data from a Phase 1 Single Ascending Dose study of PYC-001. This investigational drug candidate targets Autosomal Dominant Optic Atrophy, a genetic disease with no current treatments. The Phase 1/2 Multiple Ascending Dose study will now evaluate the safety and efficacy of repeat doses of PYC-001 in various cohorts, with results expected to be shared in 2026 and 2027.
Key Points
  • PYC Therapeutics Limited is advancing an investigational drug candidate, PYC-001, for Autosomal Dominant Optic Atrophy (ADOA).
  • The Safety Review Committee (SRC) approved progression from single-dose to multiple-dose studies after reviewing 4-week safety data on a 60 microgram dose.
  • The Phase 1/2 Multiple Ascending Dose (MAD) study will now include evaluation of repeat doses of 60 micrograms, alongside 10 and 30 microgram cohorts.
  • PYC Therapeutics focuses on RNA therapies for genetic diseases with no treatment options.
  • Data from the ongoing Phase 1/2 MAD study will be presented throughout 2026 and 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.